[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Sign-in]  [Mail]  [Setup]  [Help] 

Status: Not Logged In; Sign In

Sounds Like They're Trying to Get Ghislaine Maxwell out of Prison Mississippi declared a public health emergency over its infant mortality rate (guess why) Andy Ngo: ANTIFA is a terrorist organization & Trump will need a lot of help to stop them America Is Reaching A Boiling Point The Pandemic Of Fake Psychiatric Diagnoses This Is How People Actually Use ChatGPT, According To New Research Texas Man Arrested for Threatening NYC's Mamdani Man puts down ABC's The View on air Strong 7.8 quake hits Russia's Kamchatka My Answer To a Liberal Professor. We both See Collapse But.. Cash Jordan: “Set Them Free”... Mob STORMS ICE HQ, Gets CRUSHED By ‘Deportation Battalion’’ Call The Exterminator: Signs Demanding Violence Against Republicans Posted In DC Crazy Conspiracy Theorist Asks Questions About Vaccines New owner of CBS coordinated with former Israeli military chief to counter the country's critics, BEST VIDEO - Questions Concerning Charlie Kirk, Douglas Macgregor - IT'S BEGUN - The People Are Rising Up! Marine Sniper: They're Lying About Charlie Kirk's Death and They Know It! Mike Johnson Holds 'Private Meeting' With Jewish Leaders, Pledges to Screen Out Anti-Israel GOP Candidates Jimmy Kimmel’s career over after ‘disgusting’ lies about Charlie Kirk shooter [Plus America's Homosexual-In-Chief checks-In, Clot-Shots, Iryna Zarutska and More!] 1200 Electric School Busses pulled from service due to fires. Is the Deep State Covering Up Charlie Kirk’s Murder? The FBI’s Bizarre Inconsistencies Exposed Local Governments Can Be Ignorant Pissers!! Cash Jordan: Gangs PLUNDER LA Mall... as California’s “NO JAILS” Strategy IMPLODES Margin Debt Tops Historic $1 Trillion, Your House Will Be Taken Blindly Warns Dohmen Tucker Carlson LIVE: America After Charlie Kirk Charlie Kirk allegedly recently refused $150 million from Israel to take more pro Israel stances "NATO just declared War on Russia!"Co; Douglas Macgregor If You're Trying To Lose Weight But Gaining Belly Fat, Watch Insulin Arabica Coffee Prices Soar As Analyst Warns of "Weather Disasters" Risk Denting Global Production Candace Owens: : I Know What Happened at the Hamptons (Ackman confronted Charlie Kirk)

Health
See other Health Articles

Title: Sanofi, Regeneron arthritis drug meets goals in Phase 3 trial.
Source: [None]
URL Source: [None]
Published: Nov 22, 2013
Author: staff
Post Date: 2013-11-22 04:50:14 by Tatarewicz
Keywords: None
Views: 7

Yahoo Finance PARIS, Nov 22 (Reuters) - An experimental drug for rheumatoid arthritis developed by French drugmaker Sanofi and Regeneron, when combined with methotrexate, improved symptoms and physical function and slowed progression of the disease in a late-stage clinical trial.

Rheumatoid arthritis is an autoimmune disease in which thebody's immune system mistakenly attacks healthy tissue, causing inflammation and pain in the joints.

Sanofi and Regeneron's drug, called sarilumab, is an injectable antibody that works by blocking an inflammation-causing protein called interleukin 6. It is similar to Actemra, Roche's fast-growing treatment approved in 2010.

The success of the trial pushes the new drug one step closer to the production line, although it still to pass further long-term trials and the approval process in particular markets.

The 52 week SARIL-RA-MOBILITY Phase 3 trial enrolled some 1,200 patients with active, moderate-to-severe rheumatoid arthritis, who have not benefited from or been able to tolerate the standard oral treatment, methotrexate, whose side effects can include nausea and liver damage.

Patients given a 200 mg dose of sarilumab every other week on top of methotrexate saw a 66 percent improvement in signs and symptoms of rheumatoid arthritis after six months, Sanofi and Regeneron said in a statement on Friday.

Those given a 150 mg dose saw a 58 percent improvement,while those given a placebo alongside methotrexate saw a 33 percent improvement.

Sarilumab met the other two primary endpoints of the study,improving physical function at week 16 and inhibiting progression of joint damage after one year, the companies said.

Infections were the most frequently reported adverse side effects, as well as increases in "bad" LDL cholesterol and transaminases, they added.

Sarilumab, alongside cholesterol drug alirocumab, is one of the promising products Sanofi is developing under its partnership with U.S. biotech Regeneron to offset the loss of patents on once top-selling drugs like blood thinner Plavix.

Post Comment   Private Reply   Ignore Thread  

[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Sign-in]  [Mail]  [Setup]  [Help]